Ira Pastor, ideaXme longevity and aging ambassador and founder of Bioquark interviews Luba Greenwood J.D. , Strategic Business Development and Corporate Ventures, Verily (Google Life Sciences), Board Member Mass Bio and Brooklyn ImmunoTherapeutics LLC.
Ira Pastor comments:
Member Mass Bio and Brooklyn ImmunoTherapeutics LLC. Photo Credit: Verily
In 2019 we have surpassed $7 trillion in total annual healthcare expenditures around the globe. As part of that $7 trillion, we’re now spending close to $1 trillion a year on pharmaceutical products, $350 billion on medical devices and $200 billion on new Life Sciences R&D.
From Big Tech to Health
Equally fascinating to note are the names of organizations becoming involved in this space in 2019. From a U.S. centric perspective, 15 years ago when evaluating Healthcare Clinic, the first thing that would come to mind would be Kaiser Permanente. Not Apple, Medical Devices, Baxter or Medtronic or Amazon. For pharmaceuticals, you would think of Merck, Pfizer, Novartis, etc.; Not Google or Alphabet Inc. and their Calico longevity drug development initiatives.
Yet in the last couple of years alone, these big tech companies have all made major strategic moves into health care, with the goal of using their Silicon Valley-honed skills (and major piles of cash) to try and disrupt the industry with various “moon shot” thinking, and the interests of these companies are really quite diverse from their core businesses.
Luba Greenwood
So – for today’s guest, I could think of no one better to come and talk with us for a while about this exciting evolving segment of the industry than Luba Greenwood, J.D., Head of Strategic Business Development and Corporate Ventures at Verily (formerly known as Google Life Sciences), a research organization devoted to the study of life sciences at Alphabet Inc. (formerly known as Google) – and is involved in literally “everything health and futuristic” – medical devices, wearables, nanoparticle platforms, surgical robotics, bioelectronic medicine and super-mosquitos, just to name a few.
Luba brings to Verily pharma, biotech, and digital health experience and expertise in building and investing in innovative technology companies and providing strategic counsel to global corporations. Previously, Luba has served as Vice President of Global Business Development and Mergers & Acquisitions at Roche. She is on the Board of MassBio and Brooklyn ImmunoTherapeutics, and serves as Advisor to Dana-Farber Cancer Institute, as part of its Business Development Council. Luba is a Thought Leader for the New England Journal of Medicine (NEJM) Catalyst, Founder for the Pharma Digital Health Roundtable, and a Lecturer at Boston University Law School and School of Management where she has taught courses in life sciences, business law, innovation, and entrepreneurship since 2014.
Luba’s career has spanned leadership roles in venture investing, business development, Mergers & Acquisitions, law, and operations. She previously served as Venture Partner at Colt Ventures, leading BD and Strategy for Axcella Health, a Flagship Ventures company, and served as Senior Mergers & Acquisitions Counsel at Pfizer Inc.
Luba began her career practicing law at a leading national law firm, Wilmer Cutler Pickering Hale and Dorr. Whilst there, she represented clients in securities and IP litigation matters. Luba is a recipient of several awards and honors for her work in the community, including the Science Club for Girls Catalyst Award for her commitment to advocating for women in science and technology. Luba served as non-profit board member of Longwood Symphony Orchestra, executive coach for MassNextGen, co-chair of MassBio’s Entrepreneur’s University, and mentor and judge for MassCONNECT, MIT 100K Entrepreneurship Competition, and MassChallenge.
On this show we will hear from Luba:
About her background, how she got interested in law, how she got interested in biotech, and ultimately how she finds herself in 2019 at the epicenter of science, law, and business in one of the world’s largest companies. Her views on technology “Moonshots” and where future convergence will occur between big tech and big pharma. Luba’s views about how big tech’s investments may be able to help solve the widening “valley of death” issues in biotech. Her views on novel regulatory thinking and approaches in a world of globalized medical training and research. Her views on AI/deep learning technologies in the pharma/health space. We will discuss the mentors/influencers that have helped her throughout her career.
Credits: Ira Pastor interview video, text, and audio.
If you liked this interview, be sure to check out our interview with Sjaak Vink, CEO of TheSocialMedwork!
Follow ideaXme on Twitter: @ideaxme
On Instagram: @ideaxme
On YouTube: ideaxme
Find ideaXme across the internet including on iTunes, SoundCloud, Radio Public, TuneIn Radio, I Heart Radio, Google Podcasts, Spotify and more.
ideaXme is a global podcast, ambassador and mentor programme. Our mission: Move the human story
forward!™ ideaXme Ltd.
Pingback: Rhythm and Clues: Chronobiology - ideaXme